Riskpilot← Back to searchSign inGet full accessSynpraxis i Sverige AB
ABActiveOrg 5593046005Apelvägen 12Medical specialists activities · NACE 8622Est. 20218 employees
Revenue 2025
SEK 10,3M
+11% vs 2024
EBITDA margin
11.3%
+89% vs 2024
Equity ratio
55.1%
Financial strength
Net profit 2025
SEK 820K
+103% vs 2024
| Revenue | SEK 10,3M | +11% |
| EBITDA | SEK 1,2M | +89% |
| Net profit | SEK 820K | +103% |
| Total assets | SEK 2,3M | +6% |
| Equity | SEK 1,3M | +178% |
| Employees | 8 | — |
Legal name
Synpraxis i Sverige AB
Org number
5593046005
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
1 mars 2021
Share capital
SEK 50 000
Employees
8 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva läkartjänster samt medicinsk hälso- och sjukvård, öppen specialiserad ögonsjukvård samt estetisk medicin och hudterapi och därmed förenlig verksamhet.
Address
Apelvägen 12
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 1 465 | 7 274 | 9 352 | 10 339 |
| Staff expenses | — | — | — | −4 028 |
| EBITDA | −285 | −135 | 619 | 1 171 |
| Depreciation & amort. | −109 | −209 | −216 | −211 |
| EBIT | −394 | −344 | 403 | 960 |
| Net financials | — | −1 | — | −0 |
| Profit before tax | −394 | −345 | 403 | 960 |
| Tax | −0 | −0 | −0 | −141 |
| Net profit | −394 | −345 | 403 | 820 |
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1 693 | 2 188 | 2 200 | 2 323 |
| Equity | 56 | 57 | 460 | 1 280 |
| Long-term debt | 1 050 | 704 | 0 | 0 |
| Short-term debt | 587 | 1 427 | 1 740 | 1 044 |
| Total debt | 1 637 | 2 131 | 1 740 | 1 044 |
EBITDA margin
11.3%
This company
15.8%
Market median
-28% vs market
20222025
Equity ratio
55.1%
This company
38.2%
Market median
+44% vs market
20222025
Return on equity
64.1%
This company
18.4%
Market median
+248% vs market
20222025
Net profit margin
7.9%
This company
8.1%
Market median
-2% vs market
20222025
Asset turnover
4.45×
This company
1.12×
Market median
+297% vs market
20222025
Debt / equity
0.82×
This company
0.62×
Market median
+32% vs market
20222025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-03-01 – 2022-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
LD | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Former (4) | ||
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Synpraxis i Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Daniel Andreas Boström | Audit | 0 companies |
| Nils Henrik Kristoffer Svensson | Deputy Board Member | 0 companies |
| Lina Anna Elisabeth Nordström | Deputy Board Member | 0 companies |
| Nina Marika Wodzinski | Board of Directors | 0 companies |
| Henrik Daniel Karlsson | Deputy Board Member | 0 companies |
| Eleni Evangelidou | Deputy Board Member | 0 companies |
| Achillefs Filios | Chairman | 0 companies |
| Georgios Karanis | Board of Directors | 0 companies |